Trial comparing treatments for DLBCL - Diffuse Large B Cell Lymphoma
Official title Modified DHAP Versus Standard DHAP in Relapsed/Refractory Diffused Large B-cell Lymphoma.
ClinicalTrials.gov ID: NCT07739654
What this study is testing
What is Cisplatin (modified schedule)?
Cisplatin (modified schedule) is an investigational medicine, given as an IV infusion (through a vein), being studied as a potential treatment for dlbcl - diffuse large b cell lymphoma.
Plain-language explanation of the investigational treatment. It is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- This Phase III randomized controlled trial evaluates the effectiveness and toxicity profile of a modified DHAP regimen compared to the standard DHAP regimen in adult patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL). The DHAP regimen (cisplatin, cytarabine, dexamethasone) is widely used as salvage therapy but is associated with significant toxicities, including renal dysfunction and severe myelosuppression.
- Phase 3: a large, late-stage study
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Histologically confirmed relapsed or refractory DLBCL
- Adults ≥ 18 years
- At least one prior line of therapy for lymphoma
- ECOG performance status 0-2
- Ability to provide informed consent and comply with study requirements
You likely can't join if
- History of other malignancies within last 5 years (except non-melanoma skin cancer or localized prostate cancer)
- Pregnant or breastfeeding women
- Significant uncontrolled medical conditions (e.g., cardiovascular disease, uncontrolled diabetes)
- Receipt of investigational agents within 30 days prior to enrollment
- Known severe allergic reactions to DHAP components (dexamethasone, cytarabine, cisplatin)
- Concurrent anti-cancer treatments (chemotherapy, radiotherapy) during study period
See the full eligibility criteria
- Histologically confirmed relapsed or refractory DLBCL
- Adults ≥ 18 years
- At least one prior line of therapy for lymphoma
- ECOG performance status 0-2
- Ability to provide informed consent and comply with study requirements
- Hematologic: ANC ≥ 1,000 cells/mm³, Platelets ≥ 75,000 cells/mm³
- Renal: Serum creatinine ≤ 1.5 × ULN
- Hepatic: Total bilirubin ≤ 1.5 × ULN, AST/ALT ≤ 2.5 × ULN (if no liver metastases)
- History of other malignancies within last 5 years (except non-melanoma skin cancer or localized prostate cancer)
- Pregnant or breastfeeding women
- Significant uncontrolled medical conditions (e.g., cardiovascular disease, uncontrolled diabetes)
- Receipt of investigational agents within 30 days prior to enrollment
- Known severe allergic reactions to DHAP components (dexamethasone, cytarabine, cisplatin)
- Concurrent anti-cancer treatments (chemotherapy, radiotherapy) during study period
The study team makes the final eligibility decision.
Where it is enrolling
- Lahore, Punjab Province, Pakistan
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part, but confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
This study is enrolling now at Lahore, Punjab Province, Pakistan. Enter your location above to see the nearest enrolling site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool that is independent of the study sponsor. Details come from ClinicalTrials.gov. The study team decides eligibility, and your own doctor gives medical advice.